Surgery Partners, Inc. SGRY Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Surgery Partners, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.
The official record: Surgery Partners, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Surgery Partners, Inc.'s cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Surgery Partners, Inc.'s cash & equivalents?
- Surgery Partners, Inc. (SGRY) reported cash & equivalents of $182.3M in Q1 2026.
- How has Surgery Partners, Inc.'s cash & equivalents changed year-over-year?
- Surgery Partners, Inc.'s cash & equivalents decreased by 20.5% year-over-year, from $229.3M to $182.3M.
- What is the long-term trend for Surgery Partners, Inc.'s cash & equivalents?
- Over 5 years (2020 to 2025), Surgery Partners, Inc.'s cash & equivalents has grown at a -5.5% compound annual growth rate (CAGR), from $318.2M to $239.9M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.